RxDoctor Payments Data

Ahmad Aswad

Critical Care Medicine · Miami, FLNPI 1194956987

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,529 of the $3,084 with a category attached, or 82.0%. Astrazeneca UK Limited accounts for 62.5% of it on its own, with 2 other manufacturers making up the rest.

$3,084in general payments, 2019–2025

Across 18 payments — averaging $171.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$2K
  • Eisai Inc.$1K
  • Alkermes, Inc.$21
$6,555,893in research payments, 2019–2025

Across 2,226 payments — averaging $2945.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$4.2M
  • Akebia Therapeutics Inc$2.4M

What the payments were for

  • Travel & lodging$2,52982%
  • Food & beverage$55618%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited8$1,927
Eisai Inc.9$1,136
Alkermes, Inc.1$21

How this compares

$3,084 in reported general payments places this provider in the 85th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida →

Other critical care medicine in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →